Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kangla Tsung

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The New England Journal of Medicine|April 23, 2020
First Case of Covid-19 in the United StatesKangla Tsung
Immunotherapy|August 28, 2015
An immunological view of chemotherapyKangla Tsung, Jeffrey A Norton
Oncotarget|September 15, 2017
Tumor reductive therapies and antitumor immunityHuiqin Guo, Kangla Tsung
Human Vaccines & Immunotherapeutics|September 12, 2015
In situ vaccine, immunological memory and cancer cureKangla Tsung, Jeffrey A Norton
Surgical Oncology|July 4, 2006
Lessons from Coley's ToxinKangla Tsung, Jeffrey A Norton
Surgery|September 10, 2002
Production of interferon-gamma by tumor-sensitized T cells is essential for interleukin-12-induced complete tumor eradicationNatalie C Lee, Kangla Tsung, Jeffrey A Norton
Archives of Otolaryngology--Head & Neck Surgery|July 23, 2003
Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H miceAditi H Mandpe, Kangla Tsung, Jeffrey A Norton
Annals of Surgical Oncology|December 24, 2005
Inhibition of host signal transducer and activator of transcription factor 6 results in cure with cyclophosphamide and interleukin 12 immunotherapyJeffrey A Norton, Michelle Li, Natalie C Lee, et al.
The Journal of Surgical Research|January 21, 2004
Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12Jade S Hiramoto, Kangla Tsung, Melanie Bedolli, et al.
Cancer Research|September 5, 2002
Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejectionKangla Tsung, James P Dolan, Ying L Tsung, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The New England Journal of Medicine|April 23, 2020
First Case of Covid-19 in the United StatesKangla Tsung
Immunotherapy|August 28, 2015
An immunological view of chemotherapyKangla Tsung, Jeffrey A Norton
Oncotarget|September 15, 2017
Tumor reductive therapies and antitumor immunityHuiqin Guo, Kangla Tsung
Human Vaccines & Immunotherapeutics|September 12, 2015
In situ vaccine, immunological memory and cancer cureKangla Tsung, Jeffrey A Norton
Surgical Oncology|July 4, 2006
Lessons from Coley's ToxinKangla Tsung, Jeffrey A Norton
Surgery|September 10, 2002
Production of interferon-gamma by tumor-sensitized T cells is essential for interleukin-12-induced complete tumor eradicationNatalie C Lee, Kangla Tsung, Jeffrey A Norton
Archives of Otolaryngology--Head & Neck Surgery|July 23, 2003
Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H miceAditi H Mandpe, Kangla Tsung, Jeffrey A Norton
Annals of Surgical Oncology|December 24, 2005
Inhibition of host signal transducer and activator of transcription factor 6 results in cure with cyclophosphamide and interleukin 12 immunotherapyJeffrey A Norton, Michelle Li, Natalie C Lee, et al.
The Journal of Surgical Research|January 21, 2004
Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12Jade S Hiramoto, Kangla Tsung, Melanie Bedolli, et al.
Cancer Research|September 5, 2002
Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejectionKangla Tsung, James P Dolan, Ying L Tsung, et al.
Pageof 2